Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus (Q38546981)

4 September 2017

1 reference

title

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus (English)

1 reference

4 September 2017

1 reference

Xiao-Wu Chen

1

1 reference

4 September 2017

Zhi-Xu He

2

1 reference

4 September 2017

Zhi-Wei Zhou

3

1 reference

4 September 2017

Tianxin Yang

4

1 reference

4 September 2017

Xueji Zhang

5

1 reference

4 September 2017

Yin-Xue Yang

6

1 reference

4 September 2017

Wei Duan

7

1 reference

4 September 2017

Shu-Feng Zhou

8

1 reference

4 September 2017

15 July 2015

1 reference

Clinical and Experimental Pharmacology and Physiology

4 September 2017

1 reference

4 September 2017

42

1 reference

4 September 2017

10

1 reference

4 September 2017

999-1024

1 reference

The many faces of diabetes: a disease with increasing heterogeneity

4 September 2017

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Clinical practice. Diagnosis of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Diabetes in China: a societal solution for a personal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Genomics, type 2 diabetes, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Type 2 diabetes across generations: from pathophysiology to prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Diabetic neuropathy: clinical manifestations and current treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Antidiabetic agents: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Prevention and management of type 2 diabetes: dietary components and nutritional strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Structure-function properties of prolyl oligopeptidase family enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

Prolyl endopeptidases

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Structure, function and biological relevance of prolyl oligopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

Incretin-based therapies

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Isolation of a cDNA probe for the human intestinal dipeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Glucagon-like peptide 1 and appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Dulaglutide for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Liraglutide: clinical pharmacology and considerations for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Incretin-based therapies: can we achieve glycemic control and cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin: safety, efficacy, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin benzoate for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

DPP-4 inhibitors: pharmacological differences and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Review of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin as add-on therapy for type 2 diabetes - an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

Sitagliptin: a review

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Sitagliptin for Type 2 diabetes: a 2015 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

HbA1c targets for type 2 diabetes: How many, …how far!

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12455

21 January 2018

Identifiers

DOI

10.1111/1440-1681.12455

1 reference

4 September 2017

1 reference